Once-daily dasatinib: Expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer

Urology

Volumn 77, Issue 5, 2011, Pages 1166-1171

  Yu, Evan Y ^{a,b,c,d,e,f,g,h,i,j}   Massard, Christophe ^{a,b,c,d,e,f,g,h,i,j}   Gross, Mitchell E ^{a,b,c,d,e,f,g,h,i,j}   Carducci, Michael A ^{a,b,c,d,e,f,g,h,i,j}   Culine, Stephane ^{a,b,c,d,e,f,g,h,i,j}   Hudes, Gary ^{a,b,c,d,e,f,g,h,i,j}   Posadas, Edwin M ^{a,b,c,d,e,f,g,h,i,j}   Sternberg, Cora N ^{a,b,c,d,e,f,g,h,i,j}   Wilding, George ^{a,b,c,d,e,f,g,h,i,j}   Trudel, Géralyn C ^{a,b,c,d,e,f,g,h,i,j}   Paliwal, Prashni ^{a,b,c,d,e,f,g,h,i,j}   Fizazi, Karim ^{a,b,c,d,e,f,g,h,i,j}  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e CENTRE VAL D AURELLE   (France)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h San Camillo Fortanini Hospital   (Italy)

ⁱ UNIVERSITY OF WISCONSIN   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; DASATINIB; PROSTATE SPECIFIC ANTIGEN; TELOPEPTIDE; TUMOR MARKER;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE LESION; BONE TURNOVER; CANCER RESISTANCE; CASTRATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FLUSHING; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; ISCHEMIA; MALE; METASTASIS; MUSCULOSKELETAL PAIN; NAUSEA; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOFT TISSUE DISEASE;

AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 79955610443     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.01.006     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2009;59:225-249.
2. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21-28. (Pubitemid 40052322)
3. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-245.
4. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564-1571.
5. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009; 27:2429-2435.
6. Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol. 2009;182:509-515.
7. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113:193-201. (Pubitemid 351976401)
8. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882. (Pubitemid 38807610)
9. Saad F, Chen YM, Gleason DM, et al. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer. 2007;5:390-396. (Pubitemid 47591666)
10. Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2010;28(18 suppl):LBA4507.
11. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazine-1-yl)-2-methylpyrimidin- 4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658-6661. (Pubitemid 40053752)
12. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65:9185-9189. (Pubitemid 41507982)
13. Recchia I, Rucci N, Festuccia C, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer. 2003;39:1927-1935. (Pubitemid 37311191)
14. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008;68:3323-3333.
15. Koreckij T, Nguyen H, Brown LG, et al. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer. 2009;101:263-268.
16. Luo FR, Barrett YC, Yang Z, et al. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol. 2008;62:1065-1074.
17. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15:7421-7428.
18. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204-3212.
19. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26: 1148-1159.
20. National Cancer Institute. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). Available from: www.ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ctcaev3. pdf8-9-2006. Accessed July 14, 2010.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al, for the European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
22. DePuy V, Anstrom KJ, Castel LD, et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15:869-876. (Pubitemid 47387507)
23. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998;34:2021-2026. (Pubitemid 28546935)
24. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860-1867. (Pubitemid 47557312)
25. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005-1007.
26. Rajpar S, Massard C, Laplanche A, et al. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol. 2010;21:1864-1869.
27. Pectasides D, Nikolaou M, Farmakis D, et al. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res. 2005;25:1457-1463. (Pubitemid 40546829)
28. Vinholes JJ, Purohit OP, Abbey ME, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 1997;8:1243-1250. (Pubitemid 28164080)
29. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925-4935. (Pubitemid 46223998)
30. Armstrong AJ, Creel P, Turnbull J, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008;14:6270-6276.